Researchers identified blood-based biomarkers that predict which glioblastoma patients respond best to the oncolytic virus ...
Researchers at The University of Texas MD Anderson Cancer Center have identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from ...
・Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported. ・Gilead’s rival therapy bulevirtide ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
Glioblastoma is a deadly brain cancer that suppresses the immune system and doesn’t respond well to available therapies Researchers engineered a cancer-targeting virus that can be injected directly in ...
ISLAMABAD: The Ministry of Health and the Drug Regulatory Authority of Pakistan (Drap) have launched work to combat the Hepatitis Delta Virus (HDV), a major cause of liver cirrhosis. According to ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive ...
– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results